AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31135731
Drug: Tight control
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight control (glucose measurements hourly and treatment for maternal glucose levels lower than 60 mg/dL or greater than 100 mg/dL)
Trial: 31135731
Drug: Liberalized control
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberalized control (glucose measurements every 4 hours and treatment for maternal glucose levels lower than 60 mg/dL or greater than 120 mg/dL)
Trial: 28543940
Drug: Romosozumab (210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romosozumab (210 mg monthly)
Trial: 23683600
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 μg daily)
Trial: 22841526
Drug: 4 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL/kg of 7.2% NaCl/hydroxyethyl starch (HSH group)
Trial: 10862445
Drug: Imipenem/cilastatin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (2 g daily)
Trial: 10862445
Drug: Meropenem (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (2 g daily)
Trial: 22580235
Drug: rhDNAse 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhDNAse 7.5 mg
Trial: 17462643
Drug: T administration
RxNorm normalized name: tablet administration aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T administration alone
Trial: 10520780
Drug: Low-dose dobutamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dobutamine echocardiography (LDDE)
Trial: 8866632
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg PROP
Trial: 8866632
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg PROP + 100 mg CAFF
Trial: 8866632
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg PROP + 150 mg CAFF
Trial: 1727457
Drug: Interactive videodisc
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive videodisc preparation
Trial: 1727457
Drug: Noninteractive videotape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninteractive videotape preparation
Trial: 6369216
Drug: BSS Plus
RxNorm normalized name: BSS Plus
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSS Plus with glucose = 400 mg/dl
Trial: 6369216
Drug: BSS Plus
RxNorm normalized name: BSS Plus
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSS Plus with glucose = 100 mg/dl
Trial: 9856918
Drug: Doxazosin 4
RxNorm normalized name: doxazosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 4 mg/day
Trial: 6347779
Drug: Interruption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interruption of continuous subcutaneous insulin infusion
Trial: 22382187
Drug: Thrice-daily biphasic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily biphasic human insulin (30/70, BHI)
Trial: 2193979
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine (half dose)
Trial: 2193979
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine (full dose)
Trial: 30834817
Drug: Interactive decision
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive decision tool intervention for FTASD treatment
Trial: 30834817
Drug: Text-based control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text-based control on shoulder dislocations and treatments
Trial: 25833773
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein supplementation (20 g/d)
Trial: 23890573
Drug: Triple-antiplatelet therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-antiplatelet therapy (TAT; aspirin, clopidogrel, and cilostazol)
Trial: 19619377
Drug: Phone-based, nurse-led
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phone-based, nurse-led educational, care coordination palliative care intervention model, provided weekly for the first month and then monthly until death, including bereavement follow-up call to the caregiver.
Trial: 17502727
Drug: Antiretroviral drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral drug resistance
Trial: 12202466
Drug: Risedronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (5 mg daily)
Trial: 9676346
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg sustained release theophylline (Bronchoretard) administered in a fasting state
Trial: 9676346
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg sustained release theophylline (Bronchoretard) administered after a standard meal
Trial: 9676346
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg sustained release theophylline (Bronchoretard) administered after a high-caloric fat evening meal
Trial: 8192698
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of food with theophylline
Trial: 7734463
Drug: Enhanced clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced clinical services (more frequent and intensive group therapy, or adding individual treatment services)
Trial: 25119509
Drug: Multidisciplinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary treatment with PMT
Trial: 17135808
Drug: Telephonic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telephonic administration of the same assessment
Trial: 12923410
Drug: Hydrochlorothiazide (HCTZ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ, 25-50 mg once daily)
Trial: 11194516
Drug: p-HES (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p-HES (1000 ml)
Trial: 11194516
Drug: c-HES (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: c-HES (1000 ml)
Trial: 3565455
Drug: Native intravenous
RxNorm normalized name: Castanea sative leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native intravenous immunoglobulin (IVIG)
Trial: 3565455
Drug: Modified intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified intravenous immunoglobulin (IVIG)
Trial: 20556817
Drug: ERB-041 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERB-041 (5 mg)
Trial: 20556817
Drug: ERB-041 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERB-041 (25 mg)
Trial: 20556817
Drug: ERB-041 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERB-041 (75 mg)
Trial: 11083963
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus nebulized salbutamol (0.2 mg/kg) and oral steroids (1 mg/kg)
Trial: 8466016
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection at vastus lateralis
Trial: 8466016
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection at vastus lateralis
Trial: 8466016
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection at deltoid
Trial: 8466016
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection at deltoid
Trial: 26551446
Drug: H5N1(2) -
RxNorm normalized name: influenza, H5N1-1203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H5N1(2) - H5N1 group (2-dose priming with A/Indonesia/05/2005-H5N1-AS03B followed by booster with A/turkey/Turkey/1/2005-H5N1-AS03B)
Trial: 8009573
Drug: IR propranolol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR propranolol, 160 mg (Phase A)
Trial: 2605788
Drug: Naloxone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (4 mg bolus and 6 mg/h)
Trial: 27676631
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (up to 20 treatments within 6 months)
Trial: 21350422
Drug: Neuromidin (ipidacrinum)
RxNorm normalized name: Neurokinin p
DrugBank: Substance P (DB19198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromidin (ipidacrinum) 80 mg/day for 3 months
Trial: 15623461
Drug: Combination low-fat/high-FV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination low-fat/high-FV diet
Trial: 7509894
Drug: Bisoprolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (10 mg once daily)
Trial: 10155349
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg once daily)
Trial: 28829001
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 34 mg of ferrous sulfate (group A)
Trial: 28829001
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of 34 mg of ferrous sulfate (group B)
Trial: 21563507
Drug: Xuebijing Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuebijing Injection
Trial: 23985210
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine therapy)
Trial: 12614996
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day of ethyl-eicosapentaenoic acid
Trial: 8409152
Drug: Intramuscular cefoperazone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular cefoperazone, 1 gm every 12 hours, for 10 days
Trial: 8409152
Drug: Intramuscular ceftriaxone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ceftriaxone, 1 gm every 24 hours, for 10 days
Trial: 3512778
Drug: Methylpentynol, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylpentynol, 200 mg/day
Trial: 29529161
Drug: Large servings
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large servings of apple (410 g)
Trial: 29529161
Drug: Large servings
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large servings of apple juice (340 mL)
Trial: 12439601
Drug: 24-hour intravenous
RxNorm normalized name: 24 Hour Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour intravenous infusions of methotrexate (MTX)
Trial: 30782915
Drug: STEP clinic
RxNorm normalized name: Plan B One-Step Clinic Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STEP clinic care including self-monitoring instructions, BP monitor, sleep apnoea screening, dietary counselling, review of BP monitoring records, and medication adjustment.
Trial: 29270490
Drug: QPI‐1002 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QPI‐1002 0.5 mg/kg
Trial: 29270490
Drug: QPI‐1002 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QPI‐1002 1.5 mg/kg
Trial: 21402549
Drug: rAd5 HIV-1
RxNorm normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAd5 HIV-1 gag vaccine
Trial: 17916806
Drug: salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salmeterol/fluticasone propionate 50/500 microg twice daily
Trial: 12616578
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) with nonexposure-based treatment
Trial: 12616578
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) with both exposure and nonexposure-based treatments
Trial: 11127455
Drug: Transvaginal progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transvaginal progesterone gel (90 mg on alternate days) with estradiol (1 mg/day for three weeks then 2 mg/day for one week)
Trial: 8262689
Drug: Morphine, 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine, 0.2 mg/kg-1
Trial: 12122623
Drug: NaCl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl (2 ml of 0.9% NaCl applied eight times daily)
Trial: 8831437
Drug: Pharmacotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy with nortriptyline
Trial: 26988845
Drug: L-based supplement
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-based supplement
Trial: 21459588
Drug: Boron neutron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boron neutron capture therapy (BNCT)
Trial: 17485918
Drug: Radioiodine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine treatment (3.3-5.6 GBq)
Trial: 15205198
Drug: Paclitaxel-Carboplatin (CRP-PCT)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Paclitaxel-Carboplatin (CRP-PCT) - CRP 6 AUC and PCT 175 mg/m² every 3 weeks for six cycles
Trial: 15205198
Drug: Paclitaxel-Vinorelbine (VRL-PCT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel-Vinorelbine (VRL-PCT) - VRL 25 mg/m² and PCT 135 mg/m² every 2 weeks for nine cycles
Trial: 7986470
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion with 3% saline infusion (0.1 mL/kg/min)
Trial: 7986470
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion (2 ng/kg/min) alone
Trial: 2645421
Drug: Enoxacin 400
RxNorm normalized name: enoxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin 400 mg orally every 12 hours for 14 days
Trial: 2645421
Drug: Trimethoprim 160
RxNorm normalized name: trimethoprim 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim 160 mg plus Sulfamethoxazole 800 mg
Trial: 31992372
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil (20 g/d)
Trial: 24469530
Drug: Residual insomnia
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residual insomnia symptoms after treatment
Trial: 9440372
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g fat meal
Trial: 9440372
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g fat meal
Trial: 9440372
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g fat meal
Trial: 9440372
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g fat meal
Trial: 9440372
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g fat meal
Trial: 2151278
Drug: Zoladex depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoladex depot alone, 3.6 mg subcutaneously every 28 days
Trial: 2151278
Drug: Zoladex depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoladex depot plus cyproterone acetate (CPA), 200 mg/day orally
Trial: 345826
Drug: Phenelzine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenelzine (mean dose of 78 mg/day for 3 weeks)
Trial: 29026385
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion and Saline infusion
Trial: 25940554
Drug: 0.1 mg/ml
RxNorm normalized name: deanol 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/ml mitomycin-C (MMC) applied for 1 min
Trial: 28720121
Drug: Daily SMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SMS reminders
Trial: 16333854
Drug: PSA velocity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA velocity <= 0.0 ng/mL per month
Trial: 30192007
Drug: Rasagiline 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline 2 mg/day
Trial: 10408537
Drug: Interferon beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta‐1a (IFN‐beta) 3 MIU for 2 weeks and then 6 MIU for 10 weeks, subcutaneously three times weekly
Trial: 12000349
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health care education programme (OHCE)
Trial: 2085969
Drug: Mifepristone 600
RxNorm normalized name: Mifepristone 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 600 mg single oral dose
Trial: 25728546
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl citrate
Trial: 25693333
Drug: Sugammadex 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 0.5 mg kg‐1
Trial: 25693333
Drug: Sugammadex 8.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 8.0 mg kg‐1
Trial: 16887854
Drug: Achievement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achievement of NCEP LDL-C goal <1.8 mmol/L
Trial: 15362593
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (50 g) with atropine (0.01 mg/kg I.M. administered 15 min prior to acetaminophen ingestion)
Trial: 15362593
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (50 g) alone
Trial: 11115081
Drug: PEG-hirudin (PEG-Hi)
RxNorm normalized name: hirudin
DrugBank: Pegmusirudin (DB19220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-hirudin (PEG-Hi) 0.05 mg/kg body weight, single intravenous bolus injection
Trial: 6358278
Drug: Suberythemal dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suberythemal dose of UVB or UVA radiation
Trial: 27402064
Drug: Lulizumab pegol
RxNorm normalized name: Lulizumab pegol
DrugBank: Lulizumab pegol (DB15441)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lulizumab pegol (SC; 6.25 mg every 2 weeks, 12.5 mg weekly, 37.5 mg weekly)
Trial: 25439501
Drug: Facilitated Lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitated Lifestyle Intervention Prescription (FLIP)
Trial: 22230419
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl (isotonic) solution
Trial: 15504380
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral mifepristone followed by 400 microg oral misoprostol 2 days later
Trial: 11468134
Drug: Flupenthixol decanoate
RxNorm normalized name: flupenthixol decanoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol decanoate (10 mg, i.m. injection every second week for 6 months)
Trial: 11468134
Drug: Placebo (i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (i.m. injection every second week for 6 months)
Trial: 18640991
Drug: ET-1 infusion
RxNorm normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET-1 infusion
Trial: 24624849
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (0.2-1.4 microg kg(‐1) per hour)
Trial: 21471823
Drug: Estrogen (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen (0.625 mg conjugated estrogens)
Trial: 17364275
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg bid for 16 weeks
Trial: 7768078
Drug: Melatonin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (0.3 mg or 1.0 mg)
Trial: 28091703
Drug: Landiolol (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol (0.1, 0.2, and 0.3 mg/kg BW)
Trial: 28091703
Drug: Esmolol (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (0.5, 1, and 1.5 mg/kg BW)
Trial: 26560483
Drug: Dexamethasone 1.65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 1.65 mg
Trial: 31750699
Drug: No-treatment (NT)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment (NT)
Trial: 3511209
Drug: 3-week benzathine
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week benzathine penicillin G injections
Trial: 3511209
Drug: 4-week benzathine
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week benzathine penicillin G injections
Trial: 31690523
Drug: Intermittent vacuum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent vacuum therapy (IVT) at -50 mBar negative pressure, 12 sessions of 30 minutes over 6 weeks.
Trial: 31690523
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment at -5 mBar negative pressure, 12 sessions of 30 minutes over 6 weeks.